Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies (Nasdaq: ADVM) has granted inducement awards to two new employees under its 2017 Inducement Plan. The awards include non-qualified stock options to purchase 16,860 shares and restricted stock units (RSUs) for 8,430 shares of common stock.
The stock options have an exercise price of $3.08 per share and vest over four years, with 25% vesting in the first year and the remainder monthly over three years. The RSUs vest over three years, with one-third vesting annually. Both awards require continuous employment for vesting.
Adverum Biotechnologies (Nasdaq: ADVM) ha assegnato premi di incentivazione a due nuovi dipendenti ai sensi del suo 2017 Inducement Plan. I premi comprendono opzioni su azioni non qualificate per l'acquisto di 16.860 azioni e unit脿 di azioni vincolate (RSU) per 8.430 azioni ordinarie.
Le opzioni hanno un prezzo di esercizio di $3,08 per azione e maturano in quattro anni: il 25% nel primo anno e il resto mensilmente nei successivi tre anni. Le RSU maturano in tre anni, con un terzo che matura ogni anno. Entrambi i premi richiedono la continuit脿 dell'impiego per la maturazione.
Adverum Biotechnologies (Nasdaq: ADVM) ha otorgado premios de incentivo a dos nuevos empleados en virtud de su 2017 Inducement Plan. Los premios incluyen opciones sobre acciones no calificadas para comprar 16.860 acciones y unidades de acciones restringidas (RSU) por 8.430 acciones ordinarias.
Las opciones tienen un precio de ejercicio de $3,08 por acci贸n y se consolidan en un periodo de cuatro a帽os: el 25% en el primer a帽o y el resto mensualmente durante los siguientes tres a帽os. Las RSU se consolidan en tres a帽os, con un tercio cada a帽o. Ambos premios requieren empleo continuo para consolidarse.
Adverum Biotechnologies (Nasdaq: ADVM)電� 2017 鞚鸽崟鞀る韸� 頂岆灉鞐� 霐半澕 霊� 氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 鞚鸽崟鞀る韸� 靸侅潉 攵�鞐枅鞀惦媹雼�. 靸侅棎電� 16,860欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 牍勳瀽瓴� 欤检嫕毵れ垬靹犿儩甓�瓿� 8,430欤检潣 鞝滍暅欤�(RSU)臧� 韽暔霅╇媹雼�.
欤检嫕毵れ垬靹犿儩甓岇潣 頄夓偓臧�瓴╈潃 欤茧嫻 $3.08鞚措┌ 4雲勳棎 瓯胳硱 氩犾姢韺呺惄雼堧嫟. 觳暣鞐� 25%臧� 氩犾姢韸鸽悩瓿� 雮橂ǜ歆�電� 頄ロ泟 3雲� 霃欖晥 毵れ洈 氩犾姢韺呺惄雼堧嫟. RSU電� 3雲勳棎 瓯胳硱 毵る厔 1/3鞌� 氩犾姢韺呺惄雼堧嫟. 霊� 氤挫儊 氇憪 氩犾姢韺呾潉 鞙勴暣 瓿勳啀 攴茧臧� 頃勳殧頃╇媹雼�.
Adverum Biotechnologies (Nasdaq: ADVM) a accord茅 des primes d'incitation 脿 deux nouveaux employ茅s dans le cadre de son 2017 Inducement Plan. Les attributions comprennent des options d'achat d'actions non qualifi茅es pour 16 860 actions et des unit茅s d'actions restreintes (RSU) pour 8 430 actions ordinaires.
Les options ont un prix d'exercice de 3,08 $ par action et se trouvent en p茅riode d'acquisition (vesting) sur quatre ans : 25 % la premi猫re ann茅e et le reste mensuellement sur les trois ann茅es suivantes. Les RSU s'acqui猫rent sur trois ans, 脿 raison d'un tiers par an. Les deux attributions exigent une continuit茅 d'emploi pour l'acquisition.
Adverum Biotechnologies (Nasdaq: ADVM) hat im Rahmen seines 2017 Inducement Plan Anreizverg眉tungen an zwei neue Mitarbeiter gew盲hrt. Die Zuwendungen umfassen nicht qualifizierte Aktienoptionen zum Erwerb von 16.860 Aktien und Restricted Stock Units (RSUs) 眉ber 8.430 Stammaktien.
Die Optionen haben einen Aus眉bungspreis von $3,08 je Aktie und werden 眉ber vier Jahre vestet: 25% im ersten Jahr, der Rest monatlich 眉ber die folgenden drei Jahre. Die RSUs vesten 眉ber drei Jahre, jeweils ein Drittel pro Jahr. Beide Zuwendungen setzen f眉r das Vesting eine ununterbrochene Besch盲ftigung voraus.
- None.
- None.
REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum鈥檚 Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 16,860 shares of common stock and restricted stock units (RSUs) for 8,430 shares of common stock to two new employees under Adverum鈥檚 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price of
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy to preserve sight for life in highly prevalent ocular diseases with the aspirations of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians鈥� offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit聽.
Corporate and Investor Inquiries:
Adverum Investor Relations
贰尘补颈濒:听
Media:
Jason Awe, Ph.D.
Executive Director, Corporate Communications
Email:
FAQ
What inducement awards did Adverum Biotechnologies (ADVM) grant to new employees?
What is the exercise price for ADVM's newly granted stock options?
What is the vesting schedule for Adverum's (ADVM) new stock options?
How do the RSUs vest in Adverum's (ADVM) inducement grants?
